Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 920 results found since Jan 2013.
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
ConclusionsThis study showed that not all LABA/LAMA FDCs were superior to LABA/ICS FDCs in safety and in preventing moderate or severe exacerbations in patients with stable COPD, providing important quantitative information for COPD-related guidelines.
Source: European Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Source Type: research
Enthesitis in Spondyloarthritis Including Psoriatic Arthritis-To Inject or Not To Inject?: A Narrative Review
Clin Ther. 2023 Sep 14:S0149-2918(23)00303-X. doi: 10.1016/j.clinthera.2023.08.002. Online ahead of print.ABSTRACTPURPOSE: Enthesitis is a key manifestation of psoriatic arthritis (PsA) and spondyloarthritis (SpA) and is considered to be the tissue where the disease initiates. Enthesitis leads to pain and substantial limitations in patients with PsA. Treatment is key in achieving remission or minimal disease activity. Whether it is safe to apply injections to entheseal tissue is unknown. This narrative review aimed to summarize the literature on the efficacy and tolerability of entheseal corticosteroid (CS) injections.METH...
Source: Clinical Therapeutics - September 16, 2023 Category: Drugs & Pharmacology Authors: Ozun Bayindir Tsechelidis Ricardo Sabido-Sauri Sibel Zehra Aydin Source Type: research
Budesonide, an anti-inflammatory drug, exacerbate clostridioides difficile colitis in mice
CONCLUSIONS: Anti-inflammatory drugs including corticosteroid therapy may worsen the incidence and severity of CDI in this mouse model. These studies may have important clinical implications for understanding the role of anti-inflammatory/ corticosteroid therapy in CDI and inflammatory bowel disease management.PMID:37713991 | DOI:10.1016/j.biopha.2023.115489
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 15, 2023 Category: Drugs & Pharmacology Authors: Qianyun Lin Zitong Li Lei Lu Hua Xu Eddie Lou Alyssa Chen Dustin Sun Wuyi Zhang Weishu Zhu Eric U Yee Pamela Suzanne Sears Xinhua Chen Ciaran P Kelly Source Type: research
Prediction of the penetration depth of multi-lamellar liposomes in artificial skin. Application to the vectorization of corticosteroid in human skin
Eur J Pharm Biopharm. 2023 Sep 12:S0939-6411(23)00240-0. doi: 10.1016/j.ejpb.2023.09.007. Online ahead of print.ABSTRACTOur previous work showed that the size, elasticity and charge of multi-lamellar liposomes (MLLs) could not be considered separately to predict the fate of MLLs in the skin.[1] Based on this study, we developed several MLLs formulations containing a corticosteroid, betamethasone 17-valerate (B17) to transport the drug into the stratum corneum, living epidermis, dermis or through the skin. MLLs encapsulation efficiency was found to exceed 74 ± 3 % in all cases. In addition, we showed that MLLs protected th...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 14, 2023 Category: Drugs & Pharmacology Authors: Antoine Bernasqu é Muriel Cario St éphanie Krisa Sophie Lecomte Chrystel Faure Source Type: research
Upregulation of IL-37 in epithelial cells: A potential new mechanism of T cell inhibition induced by tacrolimus
This study showed that tacrolimus could directly upregulate the expression of IL-37 in human gingival epithelial cells by promoting the TGF-βRI/Smad3 pathway independently of calcineurin inhibition and MAPKs. In contrast, dexamethasone, one of the corticosteroids, did not have the same effect. Moreover, IL-37 could inhibit the proliferation of activated T cells and the secretion of effector cytokines and alleviate epithelial cell apoptosis and death caused by activated T cells ina co-culturesystem. Furthermore, compared with healthy controls, IL-37 and p-Smad3 levels significantly increased in the oral mucosa affected by ...
Source: Biochemical Pharmacology - September 10, 2023 Category: Drugs & Pharmacology Authors: Zhangci Su Jingyi Lu Zihang Ling Wei Li Xi Yang Bin Cheng Xiaoan Tao Source Type: research
Intravitreal immunotherapy in noninfectious uveitis: an update
Expert Rev Clin Pharmacol. 2023 Sep 6. doi: 10.1080/17512433.2023.2256660. Online ahead of print.ABSTRACTINTRODUCTION: In the past several years, there have been numerous advances in pharmacotherapeutics for the management of uveitis and other ocular inflammatory diseases, including newer therapeutic agents and ocular drug delivery systems. One of the most attractive modes of drug delivery is the intravitreal route since it has proven to be safe and efficacious and prevents unwanted systemic adverse events related to the agent.AREAS COVERED: In this review, intravitreal delivery of various pharmacotherapeutic agents for no...
Source: Pharmacological Reviews - September 7, 2023 Category: Drugs & Pharmacology Authors: Nitin Kumar Menia Sashwanthi Mohan Aniruddha Agarwal Source Type: research
Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies
CONCLUSION: Serious infection and IFI rates are high but similar to those previously described. Risk factors for serious infection included allo-HSCT and corticosteroid use. Targeted antimicrobial prophylaxis should be evaluated in prospective studies in patients on ibrutinib to reduce serious infections and IFI.PMID:37675967 | DOI:10.1093/ajhp/zxad210
Source: American Journal of Health-System Pharmacy : AJHP - September 7, 2023 Category: Drugs & Pharmacology Authors: Kenneth Tham Stacy Prelewicz Sara deHoll Deborah M Stephens Carlos A Gomez Source Type: research
An Overview of Nanotechnological Approaches for the Diagnosis and Treatment of Allergic Illness
Curr Pharm Des. 2023 Aug 28. doi: 10.2174/1381612829666230828104015. Online ahead of print.ABSTRACTAllergies are a major health issue. Allergen avoidance, antihistamines, and corticosteroids do not treat the pathology's causes, therefore long-term therapy is essential. Long-term allergen-specific immunotherapy builds immune tolerance to the allergen. Unfortunately, immunotherapies for all allergens are not available, and adverse reactions during therapy, especially in severely allergic persons, remain a worry. In this regard, cell and bio- or nanomaterial-based allergy treatments are promising. This overview covers the mos...
Source: Current Pharmaceutical Design - August 29, 2023 Category: Drugs & Pharmacology Authors: Bhupendra Sharma Rohitas Deshmukh Source Type: research
E-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) Continues: An Opportunity for Pharmacist Intervention
Ann Pharmacother. 2023 Aug 21:10600280231193770. doi: 10.1177/10600280231193770. Online ahead of print.ABSTRACTElectronic cigarette (e-cigarette), or vaping, product use-associated lung injury (EVALI) was first identified and reported in 2019, but media coverage and reporting of cases drastically decreased when the COVID-19 pandemic started in early 2020. The syndrome has continued to occur since that time and it is critical that pharmacists are aware of how EVALI presents, and when it should be considered as a potential diagnosis. Inpatient and outpatient pharmacists play a vital role in the treatment of EVALI, and should...
Source: The Annals of Pharmacotherapy - August 22, 2023 Category: Drugs & Pharmacology Authors: Miranda R Andrus Source Type: research
